Tempest Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Tempest Therapeutics, Inc. (TPST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.36 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2021-05-13
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $1.36, a 73.90% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-09-30 was $1.12, a 77.56% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-06-30 was $1.37, a 83.88% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $5.21, a 19.22% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $3.13, a 53.56% decline from fiscal 2019.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $6.74, a 30.66% decline from fiscal 2018.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $9.72.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2021-03-31 | $1.36 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $3.13 10-K · filed 2021-03-29 | |||
| 2020-09-30 | $1.12 10-Q · filed 2020-11-09 | $3.18 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | $1.37 10-Q · filed 2020-08-10 | $3.18 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | $5.21 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | $6.74 10-K · filed 2021-03-29 | |||
| 2019-09-30 | $4.99 10-Q · filed 2019-11-13 | $6.81 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | $8.50 10-Q · filed 2019-08-12 | $7.09 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | $6.45 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $9.72 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |